PMC:7299399 / 29548-30290 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T122","span":{"begin":60,"end":68},"obj":"Body_part"},{"id":"T123","span":{"begin":82,"end":86},"obj":"Body_part"},{"id":"T124","span":{"begin":102,"end":110},"obj":"Body_part"},{"id":"T125","span":{"begin":388,"end":393},"obj":"Body_part"},{"id":"T126","span":{"begin":495,"end":506},"obj":"Body_part"},{"id":"T127","span":{"begin":508,"end":510},"obj":"Body_part"},{"id":"T128","span":{"begin":648,"end":650},"obj":"Body_part"},{"id":"T129","span":{"begin":675,"end":677},"obj":"Body_part"},{"id":"T130","span":{"begin":689,"end":697},"obj":"Body_part"},{"id":"T131","span":{"begin":717,"end":719},"obj":"Body_part"}],"attributes":[{"id":"A122","pred":"fma_id","subj":"T122","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A123","pred":"fma_id","subj":"T123","obj":"http://purl.org/sig/ont/fma/fma256135"},{"id":"A124","pred":"fma_id","subj":"T124","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A125","pred":"fma_id","subj":"T125","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A126","pred":"fma_id","subj":"T126","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A127","pred":"fma_id","subj":"T127","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A128","pred":"fma_id","subj":"T128","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A129","pred":"fma_id","subj":"T129","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A130","pred":"fma_id","subj":"T130","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A131","pred":"fma_id","subj":"T131","obj":"http://purl.org/sig/ont/fma/fma86578"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T30","span":{"begin":388,"end":393},"obj":"Body_part"}],"attributes":[{"id":"A30","pred":"uberon_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T109","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"T110","span":{"begin":129,"end":132},"obj":"Disease"},{"id":"T112","span":{"begin":306,"end":341},"obj":"Disease"},{"id":"T113","span":{"begin":312,"end":341},"obj":"Disease"},{"id":"T114","span":{"begin":343,"end":347},"obj":"Disease"},{"id":"T115","span":{"begin":379,"end":401},"obj":"Disease"}],"attributes":[{"id":"A109","pred":"mondo_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A110","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A111","pred":"mondo_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"},{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A113","pred":"mondo_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A114","pred":"mondo_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A115","pred":"mondo_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/MONDO_0043726"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T277","span":{"begin":58,"end":59},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T278","span":{"begin":388,"end":393},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T279","span":{"begin":514,"end":517},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T280","span":{"begin":607,"end":614},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T219","span":{"begin":508,"end":510},"obj":"Chemical"},{"id":"T221","span":{"begin":615,"end":620},"obj":"Chemical"},{"id":"T222","span":{"begin":648,"end":650},"obj":"Chemical"},{"id":"T224","span":{"begin":675,"end":677},"obj":"Chemical"},{"id":"T226","span":{"begin":717,"end":719},"obj":"Chemical"}],"attributes":[{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A220","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A223","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A225","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A226","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A227","pred":"chebi_id","subj":"T226","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":60,"end":74},"obj":"Phenotype"},{"id":"T25","span":{"begin":102,"end":127},"obj":"Phenotype"},{"id":"T26","span":{"begin":312,"end":332},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T37","span":{"begin":167,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_0006955"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T116","span":{"begin":0,"end":578},"obj":"Sentence"},{"id":"T117","span":{"begin":579,"end":742},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"464","span":{"begin":495,"end":513},"obj":"Gene"},{"id":"465","span":{"begin":648,"end":652},"obj":"Gene"},{"id":"466","span":{"begin":675,"end":679},"obj":"Gene"},{"id":"467","span":{"begin":717,"end":721},"obj":"Gene"},{"id":"468","span":{"begin":224,"end":231},"obj":"Species"},{"id":"469","span":{"begin":456,"end":464},"obj":"Species"},{"id":"470","span":{"begin":538,"end":546},"obj":"Species"},{"id":"471","span":{"begin":654,"end":665},"obj":"Chemical"},{"id":"472","span":{"begin":703,"end":712},"obj":"Chemical"},{"id":"473","span":{"begin":730,"end":740},"obj":"Chemical"},{"id":"474","span":{"begin":28,"end":36},"obj":"Disease"},{"id":"475","span":{"begin":129,"end":132},"obj":"Disease"},{"id":"476","span":{"begin":306,"end":341},"obj":"Disease"},{"id":"477","span":{"begin":343,"end":347},"obj":"Disease"},{"id":"478","span":{"begin":379,"end":401},"obj":"Disease"},{"id":"479","span":{"begin":438,"end":443},"obj":"Disease"}],"attributes":[{"id":"A464","pred":"tao:has_database_id","subj":"464","obj":"Gene:3569"},{"id":"A465","pred":"tao:has_database_id","subj":"465","obj":"Gene:3569"},{"id":"A466","pred":"tao:has_database_id","subj":"466","obj":"Gene:3569"},{"id":"A467","pred":"tao:has_database_id","subj":"467","obj":"Gene:3569"},{"id":"A468","pred":"tao:has_database_id","subj":"468","obj":"Tax:9606"},{"id":"A469","pred":"tao:has_database_id","subj":"469","obj":"Tax:9606"},{"id":"A470","pred":"tao:has_database_id","subj":"470","obj":"Tax:9606"},{"id":"A471","pred":"tao:has_database_id","subj":"471","obj":"MESH:C502936"},{"id":"A472","pred":"tao:has_database_id","subj":"472","obj":"MESH:C000592401"},{"id":"A473","pred":"tao:has_database_id","subj":"473","obj":"MESH:C504234"},{"id":"A474","pred":"tao:has_database_id","subj":"474","obj":"MESH:C000657245"},{"id":"A475","pred":"tao:has_database_id","subj":"475","obj":"MESH:D003398"},{"id":"A476","pred":"tao:has_database_id","subj":"476","obj":"MESH:D012128"},{"id":"A477","pred":"tao:has_database_id","subj":"477","obj":"MESH:D012128"},{"id":"A478","pred":"tao:has_database_id","subj":"478","obj":"MESH:D009102"},{"id":"A479","pred":"tao:has_database_id","subj":"479","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}

{"project":"2_test","denotations":[{"id":"32519842-32325025-158521","span":{"begin":239,"end":241},"obj":"32325025"},{"id":"32519842-32192578-158522","span":{"begin":242,"end":244},"obj":"32192578"}],"text":"One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.25,97,98 This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.98 In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab)."}